Shares of Affymetrix have been on fire over the past year despite lacking any real fundamental fuel. Will this hot stock keep rising, or is it destined to crash and burn?
Diagnostics have been taking off around health care, from fast risers like Illumina to tried-and-true companies like Thermo-Fisher. Don't miss out on this health boom.
An EU approval for an HIV therapy enhancing drug, mixed late-stage reviews for another big pharmaceutical company, and a rough week for two biotech standouts are this week's top stories.
How about a 50% gain in one week? That's the worst performance among these health-care high flyers.
The details behind Roche's deal with Pacific Biosciences of California.
Is Pacific Biosciences' new arrangement with Roche a good deal? Mr. Market gives PacBio's deal a big thumbs up.
Two important things you need to know about the future of Illumina.
The medical-technology company isn't well known, but investors have pushed Waters stock up toward all-time records.
With the potential for an epidemic at hand, we look at things from a glass-half-full perspective.
Let's see what the numbers say about Illumina (ILMN).